(Q44163487)

30 November 2017

Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report (English)

1 reference

30 November 2017

0 references

1 reference

1 reference

4

1 reference

30 November 2017

Edward A Wilson

1

1 reference

30 November 2017

Shialesh Jobanputra

series ordinal

2

1 reference

30 November 2017

Robert Jackson

series ordinal

3

1 reference

30 November 2017

I Grant McQuaker

series ordinal

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

British Journal of Haematology

30 November 2017

1 reference

30 November 2017

119

1 reference

30 November 2017

128-130

1 reference

30 November 2017

1

1 reference

Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing

30 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03810.X

Treatment of Waldenstrom's macroglobulinemia with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03810.X

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03810.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03810.X

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03810.X

10.1046/J.1365-2141.2002.03810.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference